Eli Lil­ly’s $1.6B can­cer drug failed to spark even the slight­est pos­i­tive gain for pa­tients in its 1st PhI­II

Eli Lil­ly had high hopes for its pe­gy­lat­ed IL-10 drug pegilode­cakin when it bought Ar­mo last year for $1.6 bil­lion in cash. But af­ter re­port­ing a few months ago that it had failed a Phase III in pan­cre­at­ic can­cer, with­out the da­ta, its like­ly val­ue has plunged. And now we’re get­ting some ex­act da­ta that un­der­score just how lit­tle pos­i­tive ef­fect it had.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER